Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper

Industry Insight by 2FIRSTS
Apr.15.2024
Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper
JAMA retracts e-cigarette quitting study for major coding errors and doubts on accuracy, causing widespread concern and controversy.

Recently, the Journal of the American Medical Association (JAMA) retracted an article published two months ago about vaping e-cigarettes due to researchers notifying the editors of "significant coding errors" and other issues in the study.

Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper
Withdrawal page | Image source: American Medical Association Journal

 

This paper titled "Effectiveness of e-cigarettes compared with varenicline and nicotine gum for smoking cessation: a randomized clinical trial" was originally published in the January 29th issue of JAMA Internal Medicine, led by Dr. Liu Zhaobo from the Smoking Control and Respiratory Disease Prevention Department at Beijing Friendship Hospital. The researchers in this study found that in terms of helping people quit smoking, using e-cigarettes is not inferior to prescription medications and is more effective than nicotine gum. The paper has garnered widespread attention in the medical community, non-professional media, and social media.

 

Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper
Withdrawal notice | Image source: Journal of the American Medical Association

 

However, the article was later retracted.

 

The retraction notice for this paper was issued on March 29th as follows:

 

We have identified significant coding errors that are difficult to correct. We also found discrepancies in the calculations, which have raised doubts about the accuracy and reliability of the reported results. Therefore, we believe it is necessary to retract this article in order to maintain the integrity of scientific research and uphold the trust of our readers and the medical community. All co-authors have agreed to the retraction. We sincerely apologize for any inconvenience or confusion this may have caused.

 

According to the academic media Research Gate, Liu Zhao later responded to media inquiries via email, stating that the article was voluntarily retracted by the research team. He provided the following explanation in response:

 

As we explained to the editors of the Journal of the American Medical Association, following the publication of this paper, we plan to conduct a secondary analysis. In this process, we discovered that 109 participants who should have been in the NRT group were incorrectly placed in the EC group, and another 109 participants who should have been in the EC group were incorrectly placed in the NRT group. We immediately conducted an analysis and found that the main results had changed, therefore, we promptly wrote a letter to the editor explaining this issue and requesting the retraction of the paper.

 

Furthermore, according to publicly available information, no other articles have been affected by these issues. According to Clarivate's Web of Science, the research findings in question have been cited once.

 

Dr. Liu Chaobo, the first author of the paper by the group called 2FIRSTS, was contacted for details regarding the withdrawal notice. Dr. Liu stated that the withdrawal notice was clearly explained and no further information could be disclosed. Additionally, a call was made to the Tobacco Control and Cessation Center at the China-Japan Friendship Hospital to inquire about the details, but the staff member who answered the call claimed to be unaware of the situation.

 

2FIRSTS will continue to follow the latest developments on the research paper and its retraction.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Company | PMI Survey: 60% of U.S. Voters Support a “New Path” for Tobacco Control, Backing Policies that Encourage Switching to Lower-Risk Alternatives
Company | PMI Survey: 60% of U.S. Voters Support a “New Path” for Tobacco Control, Backing Policies that Encourage Switching to Lower-Risk Alternatives
An article on Philip Morris International’s (PMI) website indicates that U.S. likely voters generally hold reserved or negative views of the FDA’s performance on public health and tobacco regulation, with only about 36% expressing approval. Two nationwide polls show that more than six in ten respondents support reducing smoking rates through new approaches rather than relying solely on higher taxes and restrictions; over half support policies that encourage adult smokers to switch to non-combust
Sep.03 by 2FIRSTS.ai
Products | ELFBAR Launches Limited Edition ELFA MASTER Stone in Germany, Featuring Custom Engraving and Double the Price of the Base Model
Products | ELFBAR Launches Limited Edition ELFA MASTER Stone in Germany, Featuring Custom Engraving and Double the Price of the Base Model
ELFBAR has unveiled the limited edition ELFA MASTER Stein. This new product retains the same core specifications as its standard counterpart but elevates the design with a zinc alloy body and a textured, hammered finish. It comes in two color options, Obsidian Black and Meteorite Grey. The device is now available on a German online retail site, priced at €29.99.
Aug.28 by 2FIRSTS.ai
Spain Moves to Ban Smoking and Vaping on Bar Terraces, Beaches, Stadiums, and Bus Stops
Spain Moves to Ban Smoking and Vaping on Bar Terraces, Beaches, Stadiums, and Bus Stops
Spain’s minority government has introduced a bill to prohibit smoking and the use of e-cigarettes in outdoor venues such as beaches, bar and restaurant terraces, bus stops, and sports stadiums. The proposal—framed as a public-health measure—faces a fragmented parliament and hospitality-sector pushback. Unlike France’s July restrictions, Spain’s plan includes both terraces and e-cigarettes. The bill excludes plain packaging; Spain records over 50,000 smoking-related deaths annually.
Sep.10
Ukraine intercepts approximately $40,000 worth of smuggled goods, including a large amount of Elfbar e-cigarettes
Ukraine intercepts approximately $40,000 worth of smuggled goods, including a large amount of Elfbar e-cigarettes
An e-cigarette smuggling operation was uncovered in the Lviv region of Ukraine, resulting in the seizure of 7,500 Elfbar e-cigarettes, valued at over 1.8 million hryvnia (approximately $40,000). The case is under investigation under Ukrainian criminal law.
Sep.23 by 2FIRSTS.ai
U.S. Conservative Commentator Charlie Kirk on Vaping Policy: Crackdown on Independent Vape Firms Could Force Adult Users Back to Cigarettes and the Black Market
U.S. Conservative Commentator Charlie Kirk on Vaping Policy: Crackdown on Independent Vape Firms Could Force Adult Users Back to Cigarettes and the Black Market
Charlie Kirk published an opinion piece in April criticizing current e-cigarette regulations, arguing that excessive oversight and litigation are not genuinely aimed at protecting youth but rather driven by political and corporate interests. He noted that this approach would force millions of adult users to lose access to low-risk alternatives, potentially pushing them back to cigarettes or toward black market products, ultimately harming public health.
Sep.11 by 2FIRSTS.ai